APA (7th ed.) Citation

G, S., L, C., M, C., D, C., V, P., G, C., . . . P, D. P. (2026). Long-term therapy with elexacaftor/tezacaftor/ivacaftor improves cystic fibrosis lung disease and monocyte function. Respiratory medicine, 260, 108930. https://doi.org/10.1016/j.rmed.2026.108930

Chicago Style (17th ed.) Citation

G, Sangiorgi, Cavinato L, Cristoferi M, Chiappetta D, Pastore V, Cimino G, Cimino L, Ascenzioni F, and Del Porto P. "Long-term Therapy with Elexacaftor/tezacaftor/ivacaftor Improves Cystic Fibrosis Lung Disease and Monocyte Function." Respiratory Medicine 260 (2026): 108930. https://doi.org/10.1016/j.rmed.2026.108930.

MLA (9th ed.) Citation

G, Sangiorgi, et al. "Long-term Therapy with Elexacaftor/tezacaftor/ivacaftor Improves Cystic Fibrosis Lung Disease and Monocyte Function." Respiratory Medicine, vol. 260, 2026, p. 108930, https://doi.org/10.1016/j.rmed.2026.108930.